October 2007: Dr. Fujii invited to speak at the Western Regional Meeting of the ACS.

July 2007: NIAID grant to evaluate selected Aspergillus antigens as potential candidates for vaccine development pending.

July 2007: Presentation of HSV2 findings at the 2007 American Society of Virology Annual Meeting.

July 2007: NCI grant to explore feasibility of commercial manufacturing methods for breast cancer therapeutic funded.July 2007: Dr. Fujii invited to share status of current projects with BARDA.

2001

    * Registered Trademark for VesiVax in November.

    * Phase I SBIR grant awarded for developing a targeted leukemia delivery system in August.

    * Phase I STTR grant awarded to provide anticancer formulations through a subcontract with a biotechnology company in July.

    * SCORE grant awarded in collaboration with the California State Polytechnic University Pomona for continuing the development of the HSV-2 vaccine technology.

    * Vaccine presentations of "Protection in Mice against Intravaginal Challenged with Herpes Simples Virus Type 2 (HSV2) Associated with Novel Liposomal gD Vaccine (LDVac)" and "Efficacy of P6 Liposomal Vaccine Compared to Inactivated NTHi Mixed with Different Adjuvants in Non-Typeable Haemophilus influenzae (NTHi) Challenged Weanling Rats" at the General Meeting of the American Society of Microbiology in Orlando, Florida in May.

    * Invited to give Oral presentations of "Long Term Effects of a Novel Liposomal gD Vaccine on Minimizing Intravaginal herpes Simplex Virus Infections in Mice", "Improved Efficacy of a Herpes Simplex Virus gD Vaccine Following Incorporation of Viral Epitope and Adjuvant in Liposomes" and a poster presentation abstract of "Efficacy of Varying P6 Liposomal Vaccine Compared to Inactivated NTHi in Non-Typeable Haemophilus influenzae (NTHi) Challenged Weanling Rats" at the 4th annual Vaccine Research Conference in Arlington, Virginia in April.

2000

    * Winner of a California Technology Investment Partnership (CalTIP) award in September ($50,000) as one of the top innovative technology companies in the state.

    * California Breast Cancer Research Program grant awarded in collaboration with USC in July.

    * Phase I SBIR grant awarded for utilizing Molecular GPS to target cancer cells a targeted liposome system in April.

    * In April, presented at the Liposome Research Days Conference " Efficacy of Liposomal Herpes Simplex Virus Type 2 (HSV-2) gD Vaccine (lgDVac) in Murine HSV-2 Intravaginal and Systemic Models".

1999

    * Patent application covering the vaccine technology filed in September.

    * Winner of a California Technology Investment Partnership (CalTIP) award in August ($150,000) as one of the top innovative technology companies in the state.

    * Phase I SBIR grant awarded for developing an Influenza vaccine in March.

1998

    * Presentation of the initial vaccine results at the 38th annual Interscience Conference on Antimicrobial Agents and Chemotherapy in September.

    * Phase I SBIR grant awarded for developing an HIV vaccine in August.

    * Phase I SBIR grant awarded for developing an HSV2 vaccine in June.

1996

    * Molecular Express founded in April